Literature DB >> 26330504

CCR 20th Anniversary Commentary: Triple-Negative Breast Cancer in 2015—Still in the Ballpark.

Steven A Narod1, Rebecca A Dent2, William D Foulkes3.   

Abstract

The research article by Dent and colleagues, which was published in the August 1, 2007, issue of Clinical Cancer Research, provided a clinical description of metastatic progression of triple-negative breast cancers. Finding successful treatment strategies for women with triple-negative breast cancer remains a challenge. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26330504     DOI: 10.1158/1078-0432.CCR-14-3122

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  3 in total

1.  Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer.

Authors:  Charles J Bowerman; James D Byrne; Kevin S Chu; Allison N Schorzman; Amanda W Keeler; Candice A Sherwood; Jillian L Perry; James C Luft; David B Darr; Allison M Deal; Mary E Napier; William C Zamboni; Norman E Sharpless; Charles M Perou; Joseph M DeSimone
Journal:  Nano Lett       Date:  2016-12-22       Impact factor: 11.189

2.  The Marine Natural Product Furospinulosin 1 Induces Apoptosis in MDA-MB-231 Triple Negative Breast Cancer Cell Spheroids, But Not in Cells Grown Traditionally with Longer Treatment.

Authors:  Esther A Guzmán; Tara P Pitts; Priscilla L Winder; Amy E Wright
Journal:  Mar Drugs       Date:  2021-04-28       Impact factor: 5.118

3.  Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer.

Authors:  Ching-Wen Chou; Yu-Min Huang; Yu-Jia Chang; Chien-Yu Huang; Chin-Sheng Hung
Journal:  Int J Med Sci       Date:  2021-04-26       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.